Amubarvimab (BRII-196), a human IgG1 monoclonal antibody (mAb), targets non-competing epitopes on the receptor binding domain (RBD) of the spike protein, exhibiting a dissociation constant (K D) of 5.88 nM. It has demonstrated efficacy in neutralizing SARS-CoV-2 variants [1] [2].